Search
Vertex Pharmaceuticals Inc
VRTXAdd to Watchlist
466.820USD
+15.190+3.36%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
118.65BMarket Cap
27.45P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.36%
5 Days
+3.63%
1 Month
+7.43%
6 Months
+1.41%
Year to Date
+2.97%
1 Year
+5.89%
Key Figures
456.170Open
467.935High
2.03MVolume
27.45P/E TTM
21.44P/E Dynamic
--Dividend TTM
0.80%Turnover Ratio
451.630Prev. Close
453.210Low
804.54MTurnover
LossP/E Static
6.13P/B
0.00%Div Yield TTM
17.58%ROA
510.77052wk High
1.21Volume Ratio
-535.60MNet Profit
254.16MShares
17.0036EPS TTM
0.37Beta
24.20%ROE
362.50052wk Low
3.26%Amplitude
86.85%Gross Margin
118.65BMarket Cap
2.62Reward/Risk
1.59%Risk Rate
TradingKey Stock Score of Vertex Pharmaceuticals Inc
Currency: USD Updated: 2026-06-22Key Insights
Vertex Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 3 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 549.86.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vertex Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
39°C
Very Low
Very High
Positive+
Vertex Pharmaceuticals Inc Highlights
StrengthsRisks
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.60% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 27.45, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 247.47M shares, decreasing 1.82% quarter-over-quarter.
Held by Manning & Napier Group, LLC
Star Investor Manning & Napier Group, LLC holds 225.29K shares of this stock.
Analyst Rating
Based on
34
analysts
Buy
Current Rating
549.861
Target Price
+21.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vertex Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vertex Pharmaceuticals Inc Info
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Ticker SymbolVRTX
CompanyVertex Pharmaceuticals Inc
CEOKewalramani (Reshma)
Websitehttps://www.vrtx.com/
Related Instruments
+0.50%
+1.28%
+0.83%
+6.26%
+1.27%
+1.42%
+2.11%
+0.90%
+6.27%
-0.54%
+1.30%
+0.14%
-1.38%
-0.73%
0.00%
+0.41%
+2.98%
+0.40%
-1.09%Popular Instruments
73.965
-0.024 (-0.03%)
297.230
-0.780 (-0.26%)
208.780
-1.910 (-0.91%)
4151.410
-38.840 (-0.93%)
732.810
-13.420 (-1.80%)
2273.370
+88.620 (+4.06%)
1213.000
+79.010 (+6.97%)
349.710
-18.320 (-4.98%)
64054.510
-349.290 (-0.54%)
404.920
+4.430 (+1.11%)
FAQs
What is the current price of Vertex Pharmaceuticals Inc (VRTX)?
The current price of Vertex Pharmaceuticals Inc (VRTX) is 466.82.
What is the symbol of Vertex Pharmaceuticals Inc?
The ticker symbol of Vertex Pharmaceuticals Inc is VRTX.
What is the 52-week high of Vertex Pharmaceuticals Inc?
The 52-week high of Vertex Pharmaceuticals Inc is 510.77.
What is the 52-week low of Vertex Pharmaceuticals Inc?
The 52-week low of Vertex Pharmaceuticals Inc is 362.50.
What is the market capitalization of Vertex Pharmaceuticals Inc?
The market capitalization of Vertex Pharmaceuticals Inc is 118.65B.
Is Vertex Pharmaceuticals Inc (VRTX) currently rated as Buy, Hold, or Sell?
According to analysts, Vertex Pharmaceuticals Inc (VRTX) has an overall rating of Buy, with a price target of 549.86.
What is the Earnings Per Share (EPS TTM) of Vertex Pharmaceuticals Inc (VRTX)?
The Earnings Per Share (EPS TTM) of Vertex Pharmaceuticals Inc (VRTX) is 15.46.
